Autism Spectrum Disorder Trial, Recruiting (NCT06877715)

Autism Spectrum Disorder Trial, Recruiting NCT06877715 Sponsor: University Hospital, Toulouse Condition: Autism Spectrum Disorder

Printed from Voxsanity (voxsanity.com.au) — NCT06877715 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Autism Spectrum Disorder

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child has been diagnosed with Prader-Willi Syndrome (PWS) confirmed by genetic testing, and their specific genetic type has been identified
The child is between 3 and 16 years old
The child already has a hospital visit or specialist team appointment planned for their routine PWS care at one of the participating centres
The child's parents or legal guardians do not object to their participation

Who may not be able to join:

The child has had any changes to their mental health or behavioural medications (such as starting, stopping, or changing the dose) in the last 3 months
It is not possible to give the parents or legal guardians clear and understandable information about the trial
The child is not covered by social security (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sophie Cabal, University Hospital of Toulouse

Phone: 0561777204

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06877715

Sponsor: University Hospital, Toulouse

Phase: Not Applicable

Status: Recruiting

Condition: Autism Spectrum Disorder

Trial contact: 0561777204

More information: https://clinicaltrials.gov/study/NCT06877715

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child has been diagnosed with Prader-Willi Syndrome (PWS) confirmed by genetic testing, and their specific genetic type has been identified
The child is between 3 and 16 years old
The child already has a hospital visit or specialist team appointment planned for their routine PWS care at one of the participating centres
The child's parents or legal guardians do not object to their participation

Who may not be able to join:

The child has had any changes to their mental health or behavioural medications (such as starting, stopping, or changing the dose) in the last 3 months
It is not possible to give the parents or legal guardians clear and understandable information about the trial
The child is not covered by social security (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital, Toulouse

Registry

ClinicalTrials.gov

Start date

7 April 2025

Est. completion

30 October 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Composite criteria : Autistic Symptomatology in Children with Prader-Willi Syndrome: Prevalence, Symptom Specificity, and Variability by Age and Genetic Subtype

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov